Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

If you have prostate cancer, your health care provider may have told you about a medicine called Nubeqa (darolutamide). The FDA approved Nubeqa in 2019. It is commonly used to treat prostate cancer ...

Johnson & Johnson JNJ announced that the FDA approved its precision therapy, Akeega (niraparib and abiraterone acetate dual-action tablet), for a second indication in prostate cancer. The agency has ...

LONDON (Reuters) - Britain's drug watchdog has reversed a controversial decision not to fund a new prostate cancer pill that was developed in the country after maker Johnson & Johnson agreed a new ...

One in six men will be diagnosed with prostate cancer. If the cancer spreads, treatment options start to dwindle, but a new pill is offering some men new hope.

For more than 80 years, men have been told that testosterone helps prostate cancer grow. But a very different picture has ...

A doctor says they are linked to increased rates of lung cancer, prostate cancer, bowel cancer, and breast cancer ...

March 8 (Reuters) - Johnson & Johnson's drug for advanced prostate cancer, Zytiga, was deemed so beneficial in patients who had not received chemotherapy that safety advisors said those in the placebo ...

If you or a loved one has prostate cancer, you may be interested in learning about medicines used to treat it. One option is a medicine called Erleada (apalutamide). The FDA approved Erleada in 2018.

CHICAGO -- There is more evidence that taking vitamin E pills can be risky. A study that followed up on men who took high doses of the vitamin for about five years found they had a slightly increased ...

A University of Kentucky Markey Cancer Center study reveals how prostate cancer cells adapt their metabolism to thrive in ...